COH AR 2006

7/31/2019 COH AR 2006

1/54

c o l l a b o r a t i o n s 2006Annual Report

7/31/2019 COH AR 2006

2/54

1 Introduction

2 Leadership Message

4 Guarding Young Lives

8 Speeding Gene Therapies

12 Advancing Against Diabetes

16 Designing Smarter Drugs

20 Defeating Drug Resistance

24 Uniting Against Infection 28 Partners in Hope

32 Financials

38 Programs and Facilities

40 Research and Clinical Divisions, Departments and Programs

42 Administrative Leadership and Board of Directors

44 Faculty Leadership

50 Locations

7/31/2019 COH AR 2006

3/54

C i t y o f H o p e |

C o l l a b o r a t i o n s

Great discoveries and improvements invariably involve the

cooperation of many minds.alexander graham bell

Ct of Hope s an oranzaton stronl rooted n

enlhtened compasson. That compasson sexpressed not onl throh the care of patents,

bt also throh the dal qest for scentc

breakthrohs. For cancer patents here and

arond the world, tme s rretreabl precos.

Or crtcal oal to shorten the tme from ntal

scentc dea to new practcal treatment

nspres or researchers to work nselshl wth

scentc and medcal colleaes arond the

world. Ths shared son and collaboraton pas

off n dscoeres n basc scence, translatonal

research and, ltmatel, lfe-chann and lfe-

san medcal care.

7/31/2019 COH AR 2006

4/54

| C i t y o f H o p e

When we think o historys great scientists, we

oten imagine them toiling in solitude until a major

discovery thrusts them into the spotlight.

Modern-day biomedicine bears little

resemblance to that o the past. Today, scientic

researchers must join orces to speedily pursue cures

or disease.

So uickly has the worlds body o medical

knowledge grown that a scientist cannot expect

to know enough to unction alone. Each must

develop a niche o specialization an area where

the scientist reigns as an expert over a uniue and

complex domain; then, to aggressively advance

science, researchers must orm teams in which each

member has critical knowledge to oer. Only then

can ideas rom the lab move speedily rom cell

culture to the clinic.

Phlp L. Enel

Mchael A. Fredman, M.D.

7/31/2019 COH AR 2006

5/54


City o Hope symbolizes this collaborative

movement; and as City o Hope moves ahead with

its 2007-2013 strategic plan, collaborations take on

even greater importance. The strategic plan guides

the institutions expansion through key research,

clinical and education programs while maintaining

longstanding attributes, such as compassionate care,

that are central to its mission.

The strategic plan will help City o Hope

develop leading research programs in areas such as

cancer biology, experimental therapeutics and

population sciences, as well as strengthen clinical

areas o excellence, including leukemia and

lymphoma. It will build robust programs in areas

such as lung, gynecologic and musculoskeletal

cancers, among others. These aspirations are

impossible without collaboration.

The work o Smita Bhatia, M.D., M.P.H., chair

o the Division o Population Sciences, serves as just

one o several examples you will see in the ollowing

pages o this report. Bhatia studies childhood cancer

patients to deeply understand what happens later in

their lives, long ater cancer treatment. But studying

only City o Hopes patients would provide too

ew research subjects to statistically discern the

true eects o childhood cancer therapy. To ully

understand these long-term eects, Bhatia must pool

our patients with many others. She must link with

physicians and researchers across the world.

Only by combining their experiences and

unselshly sharing their data can Bhatia and her

colleagues gauge the long-term eects o cancer

treatment. As a result, the collaborating researchers

can better monitor cancer survivors health and

uality o lie and provide better guidance or

patients throughout their lives.

Just like Bhatia, other City o Hope

researchers are reaching beyond the bounds o

their oces and labs to cooperate with scientists

in Caliornia and around the globe. At the heart

o their mission: uncovering the science behind the

diseases and discovering better ways to prevent,

diagnose and treat cancer, diabetes, HIV/AIDS and

other serious illnesses.

We invite you to read about their stories, and

those o their collaborating City o Hope colleagues,

in this report.

Philip L. Engel

Chair, Board o Directors

City o Hope

Michael A. Friedman, M.D.

President and Chie Executive Ofcer

City o Hope

7/31/2019 COH AR 2006

6/54


Upper left:

Wend Lander, R.N., M.S.N.,

Ct of Hope

Center:

Ct of Hope patents, lke

the on rl shown here,

benet from the collaboraton

between cancer researchers

and clncal care proders.

Lower right:

Smta Bhata, M.D., M.P.H.,

Ct of Hope

7/31/2019 COH AR 2006

7/54


guARDiNgyOuNg LivESchildrens oncology group

The diagnosis o cancer in a child is overwhelming to amilies.

Even ater successul treatment, ears remain. Will it return?

Will a dierent cancer arise later in lie? What side eects can be

expected and can they be avoided?

Research has dramatically improved survival rates or children

with cancer, rom less than 25 percent in the 1960s to nearly

80 percent today. More than 250,000 childhood cancer survivors are

living in the United States alone. But as they mature, two-thirds will

suer chronic problems and long-term complications, such as issues

related to growth and development; one-third will have a problem

that can be lie threatening. Many will develop secondary cancers,

either due to cancer treatment or underlying causes.

Because late eects may not arise until decades ater

treatment, and because pediatric cancers are ortunately rare,

researchers and care providers must pool their resources and share

their experiences to improve long-term outcomes. City o Hope

researchers are national leaders in this eort.

Smita Bhatia, M.D., M.P.H., chair o the Division o Population

Sciences at City o Hope, and medical director, Center or Cancer

Survivorship, chairs the Late

Eects Committee o the Childrens

Oncology Group (COG), a

consortium unded by the National

Cancer Institute.

7/31/2019 COH AR 2006

8/54


COG brings together pediatric cancer experts

rom 238 hospitals in the U.S., Canada, Australia,

New Zealand, the Netherlands and Switzerland. It

acilitates the organization o large-scale, denitive

multicenter research studies needed to improve

treatments, practices and outcomes. Today, more

than 90 percent o children with cancer in the U.S.

are treated at COG-aliated cancer centers, and

about 70 percent participate in clinical trials.

Bhatia serves as principal investigator or

a COG research study looking at key adverseevents in childhood cancer survivors. Patients who

develop a secondary cancer or other problem such

as congestive heart ailure or stroke are invited to

participate in the study so that the causes o these

complications can be investigated, potentially

improving uture treatments.

At City o Hope, cancer research is strongly

integrated with clinical care, and nursing is a central

ocus o that strategy. Wendy Landier, R.N., M.S.N.,

serves as clinical director o the Center or Cancer

Survivorship, and also leads the Nursing Clinical

Practice/Survivorship Subcommittee o COG, where

she serves as vice chair o the Nursing Discipline. As

leaders within both City o Hope and COG, Landier

and Bhatia have collaborated on landmark projects

including the establishment o long-term ollow-up

guidelines or young cancer survivors and a resource

guide or all COG centers to use in their own

ollow-up programs.

Participation in COG encourages alliances.

Close ties have been established with researchers

at St. Jude Childrens Research Hospital, The

Childrens Hospital o Philadelphia, Memorial

Sloan-Kettering Cancer Center and dozens o

other institutions. A Web-based version o the

long-term ollow-up guidelines that can be tailored

or individual patients will soon be launched inpartnership with Baylor School o Medicine. As a

pilot test center or the new system, City o Hope

and its patients will benet rom instant access

to the cumulative knowledge o pediatric cancer

experts rom around the world.

Toda, more than 90 percent

of chldren wth cancer n the

unted States are treated at

Chldrens Oncolo grop-

aflated cancer centers.

7/31/2019 COH AR 2006

9/54


Ct of Hope pedatrc patents

benet from the collaborate

efforts of researchers at

Ct of Hope and dozens of other

nstttons worldwde.

7/31/2019 COH AR 2006

10/54


SPEEDiNggENE

THERAPiESnational gene vector laboratoryThe most powerul weapons against cancer, diabetes and other

serious diseases cannot be seen. They are genes bits o DNA that

can be delivered to wayward cells, xing problems at the source.

Gene therapy holds huge potential or uture cures. But rening these

genetic tools, manuacturing them in uantity and getting them into

clinical trials is a major challenge on all ronts: technical, analytical

and regulatory.

The National Gene Vector Laboratory (NGVL) at City o Hope

is helping make it happen. Located within the Center or Biomedicine

& Genetics (CBG), the NGVL is the rst large-scale acility or

manuacturing biological therapeutics at an academic research center

in the United States. Here, promising new genetic and cellular agents

created by researchers can move into production rapidly, so that they

can be entered into clinical trials without delay.

The two-story, 20,000-suare-oot CBG acility was built

in 2000 with the purpose o creating an unlimited array o novel

therapeutics. Led by Larry A. Couture, Ph.D., the CBG currently

produces islet cells that treat type 1 diabetes, monoclonal antibodies

that ght cancer, engineered T-cells or immunotherapeutic clinical

trials, cancer vaccines, viral vectors or gene therapy against HIV,

and hematopoietic cell products

to treat blood disorders. Process

development is also beginning on

two types o recombinant proteins,

similar to the way City o Hope

achieved a breakthrough in the

development o synthetic human

insulin nearly 20 years ago.

7/31/2019 COH AR 2006

11/54


Lower left:

Larr A. Cotre, Ph.D., Ct of Hope

Center:

Ct of Hope manfactres

nestatonal noel therapetcs for

researchers arond the contr.

Upper Right:

Mchael C. Jensen, M.D. ,

Assocate Char,

Dson of Cancer immnotherapetcs

and Tmor immnolo, Ct of Hope

7/31/2019 COH AR 2006

12/54

0 | C i t y o f H o p e

Ct of Hopes Natonal gene vector

Laborator rapdl manfactres

bolocal therapetcs so that thesenew therapes can moe nto clncal

trals wthot dela.

1997

1998

2000

1999CBg conceed

Ma 1998

CBg fnded

Jl 1998

Bean constrcton

of CBg

Janar 1999 CBg completed

Febrar 2000

7/31/2019 COH AR 2006

13/54


produced a lentivirus vector and is a designated

back-up site or the production o adenovirus gene

therapy vectors.

With its robust manuacturing capacity and

ability to uickly produce novel therapeutics at

a small scale, the CBG provides a ast track or

scientists seeking to move their research rom bench

to bedside. It also generates valuable collabora-

tions between City o Hope and other institutions.

With material rom the NGVL, Jennier Grandics,

M.D., at the University o Pittsburgh has made rapid

progress in antisense gene therapy that can inhibit

cancer o the head and neck. At the Universityo Wisconsin, Douglas McNeel, M.D., Ph.D., is

taking a promising DNA plasmid vaccine that ghts

prostate cancer into phase II clinical trials. In the

search or better, aster cures, City o Hope is giving

researchers across the country the genetic tools they

need today.

The CBGs prolic output, scientic expertise

and certication as a Good Manuacturing Practices

acility led the National Institutes o Health (NIH)

to commission it as an NGVL, one o only ve

such acilities in the U.S. today. Specically, the

laboratory produces clinical-grade DNA plasmid

vectors or use in phase I and II clinical protocols.

DNA plasmids, also called naked DNA, are

circular pieces o DNA carrying genes that can be

transerred into cells with therapeutic eects.

Plasmids are in demand by researchers because

unlike viral vectors, they have the advantage o

producing little or no immune response. As the

only NIH-supported plasmid manuacturer in

the U.S., City o Hopes NGVL produces DNA

plasmids or all ualied, ederally unded labora-tories nationwide. In addition, the acility also has

Ct of Hope prodces

DNA plasmds for all

qaled, federall fnded

laboratores natonwde.

Desnated Sothern Calforna

islet Cell Resorce Center

September 2001

2001

2002

Frst prodcton

December 2000

Desnated

Natonal gene vector Lab

September 2001

Calforna

Food and Dr

Branch Lcense

March 2002

CbG ManUFaCtUrED ProDUCts

MANuFACTuRE PRODuCT PRODuCTDATE NAME TyPE

12/12/2001 iL-13 Plasmd DNA

1/14/2002 CE7R Plasmd DNA

7/22/2002 293 Hman Cell MCB

8/22/2002 293T Hman Cell MCB

4/17/2003 TM-LCL Hman Cell MCB

4/30/2003 L29.19 Plasmd DNA

5/23/2003 pTvg-hPAP Plasmd DNA

1/29/2004 EgFRAS Plasmd DNA

2/25/2004 T84.66 Dabod Monoclonal Antbod

6/14/2004 Ant-CD19 Plasmd DNA

1/3/2005 pHiv7-sh-TAR- Plasmd DNACCR5RZ

1/12/2005 TM-LCL Hman Cell WCB

1/20/2005 pCp Plasmd DNA

3/21/2005 pCMv-Re2 Plasmd DNA

5/12/2005 pCMv-g Plasmd DNA

6/1/2005 Lentrs vral vector6/20/2005 pHiv7-sh-TAR- Plasmd DNA

CCR5RZ

12/14/2005 gene Moded Enneered patent-specc cellsT-cell

2/15/2006 Ant-CEA hT84.66 Monoclonal AntbodM5A/NHS-DOTA

3/23/2006 pCB-AT-Zero Plasmd DNA

4/25/2006 Zenapax Monoclonal Antbod

5/2006 Lentrs vral vector

6/2006 pCMv-Re2 Plasmd DNA

8/2006 gene Moded Enneered patent-specc cellsT-cell

12/2006 CD19Rop epHiv7 Plasmd DNA

7/31/2019 COH AR 2006

14/54


Upper left:

Foad R. Kandeel, M.D., Ph.D.,

Ct of Hope

Center:

genomc analss of slet

fncton.

Lower right:

Donald C. Dafoe, M.D.,

Drector, Pancreas Transplanton,

Cedars-Sna Medcal Center

7/31/2019 COH AR 2006

15/54


ADvANCiNgAgAiNST

DiABETESislet cell transplantationThe greatest challenge in medical research is to nd a permanent cure

or a lie-threatening disease. For 5 million people around the world,

that disease is type 1 diabetes.

Also called insulin-dependent diabetes, type 1 diabetes is an

autoimmune reaction that destroys the beta cells o the pancreas.

The result is a lietime o insulin injections, threats o cardiovas-

cular, nerve and kidney disease, and dangerous low-blood-sugar

episodes. While healthy insulin-producing pancreatic islet cells can

be transplanted rom donor organs, donors are in short supply.

And transplant procedures reuire special technology, immune-

suppressing drugs and considerable expertise.

City o Hope is a leader in diabetes research, having pioneered

the development o Humulin, the synthetic human insulin that was

the rst biotechnology product approved by the Food and Drug

Administration, now used by millions o diabetics worldwide.

That leadership continues with advancing islet cell transplantation.

As one o only seven islet cell resource

(ICR) centers unded by the National

Institutes o Health, City o Hope

perormed the most islet transplants in the

United States in 2004 and 2005 and has

distributed the largest number o islets to

basic science programs in the U.S. since

2004. City o Hope is the only currently

unded ICR center in the western U.S.

In 2006, the Juvenile Diabetes Research

Foundation (JDRF) designated City o Hope

Cy f Hpe ewed

dee pgm, cudg

fevg wk e ce

p, cezed

he lee d su Gd(Gdchmed) Dee d

Geec reech Cee

Cy f Hpe.

7/31/2019 COH AR 2006

16/54


1940

1950

1970

1960Rachmel Lene, M.D., Ct of Hope,

dscoers pathophsolocal bass

of tpe 2 dabetes n 1949

as a JDRF Islet Cell Transplant Center, making it

one o only 14 in the nation and the only Southern

Caliornia organization to receive this distinction.

Three clinical trials involving islet cell

transplantation are under way at the City o Hope

Leslie and Susan Gonda (Goldschmied) Diabetes

and Genetic Research Center led by Fouad R.

Kandeel, M.D., Ph.D, director, Department o

Diabetes, Endocrinology & Metabolism. One study

seeks to improve upon the Edmonton Protocol, a

widely adopted transplant procedure reuiring two

to three islet cell inusions. Multiple inusions and

organ donors are needed because the drugs used toovercome transplant rejection are toxic to islet cells.

As an alternative, the City o Hope phase I/II trial is

employing a dierent immune suppression strategy

together with the use o growth actors to expand

the number o islet cells beore and ater transplan-

tation. The goal is to develop a single inusion that

can ree patients rom insulin dependence.

Kandeel also directs the Southern Caliornia

Islet Consortium (SC-IC), a group o institutions

sharing resources and expertise. Hosted by

City o Hope, the SC-IC includes Cedars-Sinai

Medical Center, Harbor-UCLA Medical Center,

Loma Linda Medical Center, the Southern Caliornia

Transplantation Institute, St. Vincent Medical Center,

the Whittier Institute or Diabetes/Scripps Green

Center or Organ & Cell Transplantation and the

UCLA Center or Health Sciences. Because kidney

disease is a complication o diabetes, the SC-ICs

rst multicenter clinical trial ocuses on islet cell

transplantation ater kidney transplant. City o Hope

perorms the majority o transplant procedures or

the consortium, handles regulatory reuirements

and trains physicians in islet cell techniues.

With diabetes on the rise worldwide, the

absolute shortage o islet cell donors is stimulating

the search or new islet cell strategies, including

stem cells. Looking beyond diabetes, progress

in immune tolerance achieved through islet cell

research could pave the way or advances in solid

organ transplants, cellular and gene therapies and

treatments or autoimmune conditions, Parkinsonsdisease and many other conditions that would

benet rom cell replacement.

Ct of Hope hosts the Sothern

Calforna islet Consortm,whch represents an nterated

effort of mltple academc and

transplant nstttons to mere

resorces and efforts n slet

transplantaton research.

Samal Rahbar, M.D., Ph.D.,

Ct of Hope, dscoers

HA1c n 1968

7/31/2019 COH AR 2006

17/54


yoko Fjta-yamach, Ph.D.,

Ct of Hope, dscoers cell nsln

receptor n 1982

1980

1990

2000

2010

Ct of Hope researchers work on

slet cell solaton and dstrbton

for clncal transplantaton trals

throhot the unted States.

Arthr Rs, Ph.D., and Kech itakra, Ph.D., both

from Ct of Hope, prodce snthetc nsln from

enetcall enneered bactera n1978

Establshment of the Sothern

Calforna islet Cell Resorce

Center n 2001 Stem cell transplantaton w

mmne sppresson for trea

of dabetes n the

Ct of Hope desnated as a Jenle Dabetes Research

Fondaton islet Cell Transplant Center n 2006

Lesle and Ssan gonda

(goldschmed) Dabetes and

genetc Research Center

dedcaton n 1997

7/31/2019 COH AR 2006

18/54


DESigNiNgSMARTER

DRugSmodeling g-protein coupled receptorsMany drugs in use today were created by trial and error methods

that result in a compromise: The drugs work, but carry risks o

unwanted side eects. Yet clues to designing smarter pharmaceu-

ticals with ewer side eects are hidden within the three-dimensional

structures o biomolecules that these drugs turn on or o.

Among the most important therapeutic drug targets in the

human body are G-protein coupled receptors (GPCRs) a large,

diverse group o proteins that play crucial roles in health and disease.

Woven through cell membranes, GPCRs act as signal posts, sensing

changes in the environment and directing the cell to respond. By

binding with neurotransmitters, hormones, immune substances,

odorants and other molecules, GPCRs infuence growth, metabolism,

brain response and other central lie processes. GPCRs called

chemokine receptors are also implicated in the spread and growth o

many cancers, including those o the lung, breast, prostate and colon.

With rising rates o age-related and environmental cancers, better-

targeted magic bullet GPCR drugs would have widespread benets.

In act, hal the drugs in use

today target GPCRs, activating

or inhibiting them. They are used

to lower blood pressure, combat

allergies, treat depression, calm

arthritis, heal stomach ulcers and

block pain. Yet their actions are oten

too broad, leading to side eects that

can be serious, even dangerous.

7/31/2019 COH AR 2006

19/54


Upper right:

Naarajan vadeh, Ph.D.,

Ct of Hope

Center:

3-D compter models of

protens help researchers

more qckl nestate

Wnt snal transdcton

pathwas noled n

deelopment and dsease.

Lower left:

Randall T. Moon, Ph.D.,

unerst of Washnton

P

hotobyElzabethLowry,2006

u

nverstyofWashngtonMedcne

7/31/2019 COH AR 2006

20/54


Teams of chemsts, phscsts and

compter scentsts work to prodce

rtal gPCR models, then aldate and

rene them to ltmatel brn mch-

needed gPCR drs to patents.

7/31/2019 COH AR 2006

21/54


o computers. Then, urther experiments are needed

to validate and rene the model.

But while the structures may be theoretical,

the need or progress in GPCR drugs is real.

Interest in GPCR structures is attracting pharma-

ceutical companies to work with City o Hope, and

promotes collaborations with the universities o

Caliornia, Texas, Pittsburgh and North Carolina,

Caliornia Institute o Technology, Jet Propulsion

Laboratory, New York University and Imperial

College London, among others.

At the University o Washington, scientistRandall T. Moon, Ph.D., had evidence that a

certain GPCR was involved in cancer, but needed

to understand its structure, as well as identiy

small molecules that could turn the receptor on

or o. Working together with Moon, Vaidehis

team predicted the receptors structure and rapidly

identied 20 possible modulators rom a database o

hundreds o thousands o molecules one o which

may be a perect t.

Designing the next generation o GPCR drugs

reuires data on the three-dimensional structure

o each receptor protein. But because membrane-

bound proteins are hard to crystallize, their

structures cannot be visualized directly. One solution

is to construct virtual models o these receptor

proteins using computational methods based on the

undamental laws o physics. It is a challenge that

takes teams o chemists, physicists and computer

scientists to solve.

At City o Hopes Division o Immunology,

Nagarajan Vaidehi, Ph.D., is leading the charge.

Starting with basic atomic orces, she and her

colleagues predict the theoretical 3-D structures and

binding sites o small molecules within GPCRs. Each

structure reuires months to generate, using dozens

interest n proten strctress attractn pharmacetcal

companes and nerstes

across the lobe to work wth

Ct of Hope.

7/31/2019 COH AR 2006

22/54


Upper left:

Mark E. Das, Ph.D.,

Warren and Katharne Schlner

Professor of Chemcal Enneern,

Calforna insttte of Technolo

Center:

Hman dose al of rboncleotde

redctase nhbtor sed n the rst

clncal tral.

Lower right:

yn yen, M.D., Ph.D., Ct of Hope

PhotocortesyofCalfornainsttteofTechnology

7/31/2019 COH AR 2006

23/54


DEFEATiNgDRug

RESiSTANCEribonucleotide reductase inhibitorsMany cancer drugs seem to work well at rst. But too oten, the

disease returns. And when it does, it can hit even harder and aster

than beore. Many cancers actually develop resistance to chemo-

therapy. Finding a way to deeat this drug resistance is a signicant

step toward nding a cure.

At City o Hope, Yun Yen, M.D., Ph.D., director o Clinical

and Molecular Pharmacology and co-leader o the Developmental

Cancer Therapeutics Program, believes the answer may be ound in

an enzyme that cells use naturally to repair and restore themselves.

The enzyme ribonucleotide reductase (RR) converts ribonucleotides

into the building blocks o DNA, an essential part o the normal

process o cell growth, including the ability to x damaged genes.

But in cancer cells, RR production can go into overdrive, allowing

cancers to survive attacks by chemotherapy and promoting the

spread o new malignant cells that can invade healthy tissues.

For 17 years, Yens research has ocused on understanding

the gene that codes or RR and how the enzyme itsel helps cancer

spread. One well-known chemotherapy drug, hydroxyurea, is

known to work by inhibiting RR. But i surviving cancer cells learn

to resist the drug, it can lead to recurrence. Today, Yens group is

pressing to nd more eective

anticancer agents, including

combining newer RR inhibitors

with gemcitabine, the only drug

approved or pancreatic cancer.

7/31/2019 COH AR 2006

24/54


2004

2005Branstormn sesson wth Mark E. Das, Ph.D.,

CalTech, and yn yen, M.D., Ph.D., and

Stephen J. Forman, M.D., both from Ct of Hope

Yen discovered the mechanism by which cancer

cells become resistant to gemcitabine a nding

that is actively being exploited in the search or new

cancer drugs.

Collaborative research is accelerating progress

in overcoming drug resistance. Within City o Hope,

David Horne, Ph.D., director o the Synthetic

Chemistry Core Facility, and Yate-Ching Yuan, Ph.D.,

manager o the Biomedical Inormatics Core Facility,

are designing new compounds with the ability to

inhibit RR. These are tested at City o Hopes High

Throughput Screening Core, directed by M.L.Richard Yip, Ph.D. The core acility is a resource

where newly synthesized chemicals and thousands

more rom a library o molecules can be screened

rapidly to assess whether they hold potential as

possible treatments.

Meanwhile, Yen is also working with John

Rossi, Ph.D., Lidow Family Research Chair in the

Division o Molecular Biology, to investigate the

use o small interering RNA (siRNA) to silence

the genes that produce RR through a mechanism

called RNA intererence (RNAi). Rossi is using the

RNAi approach to ght HIV, and this approach

is one o the most promising new investigational

therapies or many diseases. The 2006 Nobel Prize

in Medicine was awarded or the discovery o the

RNAi mechanism.

Taking the siRNA strategy a step urther to

a level reminiscent o science ction City o Hope

researchers are pursuing an inter-institutional project

with Mark E. Davis, Ph.D., Warren and Katharine

Schlinger Proessor o Chemical Engineering at the

Caliornia Institute o Technology, and a local start-

up company called Calando Pharmaceuticals. Davis

has engineered nanoparticles made o polymers that

can deliver drugs directly to cancer cells.

Preclinical studies conducted by Calando

Pharmaceuticals suggested that nanoparticles

containing siRNA to inhibit RR can serve as sae,

eective drug-delivery vehicles. Plans or a clinicaltrial with cancer patients are already under way.

Scentsts at Ct of Hopeand Caltech are collaboratn

to deelop nanopartcles that

can deler drs drectl to

cancer cells.

Anmal std

Jne 2005

7/31/2019 COH AR 2006

25/54


FDA approal

en for clncal tral

March 2006

2006

2007

Ct of Hope researchers prse

ntra- and nter-nstttonal

projects to nd more effecte

antcancer aents.

Preclncal std

December 2005

Frst patent enrolled

nto clncal tral

Jl 2006 Three-dose-leel testn

December 2006

Abstract sbmtted at Amercan Socet

of Clncal Oncolo annal meetn

Janar 2007

7/31/2019 COH AR 2006

26/54


uNiTiNgAgAiNST

iNFECTiONcytomegalovirus vaccineStem cell and organ transplants oer hope to patients with cancer

and other serious illnesses. But or the transplant to succeed, the

patients own immune system must be suppressed to reduce the

chance o transplant rejection. And that opens the door to inection.

Too oten, patients whose immune systems have been weakened

all victim to cytomegalovirus (CMV), a common herpes virus that

can be ound in 50 to 80 percent o adults in the United States.

Normally, inections are mild; aterward, the virus remains dormant,

held in check by a healthy immune system. But ater a transplant or

other immune-compromising event, CMV can reactivate, causing

pneumonia and other deadly diseases. About hal o bone marrow

transplant patients develop active CMV inections; the virus also is a

major cause o death in organ transplant patients.

The list goes on: CMV harms dialysis patients, causes blindness

in HIV patients and is the leading congenital inection in newborns.

CMV is responsible or hundreds o inant deaths and thousands o

serious birth deects in babies annually. The Institute o Medicine has

called the development o a CMV vaccine a national medical priority.

While antiviral drugs can be eective

against CMV, they are undesirably toxic.

As a much-needed alternative, City o Hope

scientists have teamed up to develop a CMV

vaccine, based on years o accumulated

research. Their eorts took a giant leap

orward in 2006, when the Food and Drug

Administration approved the rst human

clinical trial o a synthetic CMV vaccine.

7/31/2019 COH AR 2006

27/54


Upper right:

Don J. Damond, Ph.D.,

Ct of Hope

Center:

Ctomealors and

red blood cell.

Lower left:

John A. Zaa, M.D.,

Ct of Hope

7/31/2019 COH AR 2006

28/54


Scentsts and phscans work toether

on a phase i clncal tral to ather

data on safet, metabolsm and other

parameters of the CMv accne.

7/31/2019 COH AR 2006

29/54


M.D., chair o the Division o Virology, and

Stephen J. Forman, M.D., Francis and Kathleen

McNamara Distinguished Chair in Hematology

and Hematopoietic Cell Transplantation. Coley

Pharmaceutical Group is contributing the adjuvant.

SAIC-Frederick and the NCI sponsored the

development o early data, and the Pasteur Institute

urnished preclinical models used in establishing

the potency o the vaccine.

In the next phase, transplant donors will

receive the vaccine to evaluate whether immunity

to CMV can be transerred along with their bonemarrow or other tissues. Meanwhile, Diamond and

his colleagues are pressing ahead with a second-

generation vaccine engineered by Zhongde Wang,

Ph.D., M.D., assistant research scientist in the

Division o Virology, to combat congenital CMV,

with broader applicability in transplant recipients;

the project has received long-term unding rom

the NCI. The National Institute o Allergy and

Inectious Diseases and Bernard Moss, M.D., Ph.D.,

chie in the Laboratory o Viral Diseases, have

provided a crucial component to this project, which

is anticipated to assist in regulatory approval.

Don J. Diamond, Ph.D., director o the

Laboratory o Vaccine Research, is heading a

project in which two ormulations o the vaccine are

being tested, each with and without a biochemical

regulator called an adjuvant. At the heart o the

vaccine is a peptide molecule that originated at

City o Hope and is now being produced or urther

studies by the National Cancer Institute (NCI).

In the phase I clinical trial, currently under

way, healthy adult volunteers are being given

the vaccine in one o its orms to gather data on

saety, metabolism and other parameters. Parties

collaborating in this groundbreaking project include

Corinna La Rosa, Ph.D., assistant research scientist,

and Simon F. Lacey, Ph.D., associate researchscientist in the Division o Virology, John A. Zaia,

At the heart of the accne

s a peptde molecle that

ornated at Ct of Hope and

s now ben prodced for

frther stdes b the Natonal

Cancer insttte.

7/31/2019 COH AR 2006

30/54


7/31/2019 COH AR 2006

31/54


PARTNERS iN HOPE

A landmark number o endowed chairs, beuests, generous gits

and grants in 2006 accelerated City o Hopes uest to develop

treatments and cures or those suering rom devastating diseases.

The generous giving refected the ongoing condence o supporters in

the organizations mission.

The year was one o unprecedented generosity. City o Hope

supporters gave more than $122 million, the most ever raised in a

single year. Beuests, or donations made through wills and trusts, also

surpassed previous levels, totaling nearly $34 million. The dedicated

eorts o thousands o individuals, oundations, corporations andvolunteer groups and auxiliaries nationwide contributed to this

remarkable year, ensuring that key City o Hope research, education

and treatment programs continue to grow and progress.

Furthering a partnership that began nearly a uarter century

ago, a $20 million git rom the Arnold and Mabel Beckman

Foundation established the Arnold and Mabel Beckman Center or

Cancer Immunotherapeutics and Tumor Immunology. This modern,

108,000-suare-oot acility will blend basic science with clinical

studies and ocus on immunotherapy, a treatment that uses the

immune system to ght cancer and other diseases.

In making their git, Arnold and Mabel Beckman Foundation

leaders pledged $15 million to match a $15 million git made by an

anonymous donor, and another $5 million to spur additional gits.

Other signicant support or the acility in 2006 included a

$2 million beuest rom the estate o Diana Chudaco Levin.

The project also received a commitment rom the National

Oce Products Council, the executive advisory board o the

National Oce Products Industry, which pledged $5 million rom

the industry groups annual undraising campaigns through 2009

to support the Arnold and Mabel Beckman Center. Conseuently,

$500,000 o the industry groups 2006 contributions was

earmarked or the National Oce Products Industry Cellular and

Tumor Immunotherapies Center, which will be located on the third

foor o the Arnold and Mabel Beckman Center.

The Arnold and Mabel Beckman Center also will house

City o Hopes Center or Graduate and Proessional Studies,

which beneted rom a $750,000 grant to establish and euip the

Ralph M. Parsons Foundation Teaching Laboratory.

Other important oundation support during the year included a

$511,130 grant rom The UniHealth Foundation to enhance nursing

training, a $500,000 grant rom the Skirball Foundation to support

Me d ad beckm

7/31/2019 COH AR 2006

32/54


T-cell therapy research or lymphoblastic leukemia, a $500,000

grant rom The Henry L. Guenther Foundation to purchase a 3T

magnetic resonance imaging machine, and $450,000 rom the W.M.

Keck Foundation to und research to understand the molecular

mechanisms underlying cancer and develop new therapies that would

destroy lymphoma cells without harming normal cells.

Another critical program, transusion medicine, beneted rom

the altruism o longtime Home Furnishings Industry group supporter

Michael Amini, chairman and chie executive ocer o Amini

Innovation Corporation, who contributed a $6 million git. The three-story Michael Amini Transusion Medicine Center will consolidate

City o Hopes blood collection and processing programs and provide

a modern, comortable environment or patients, donors and sta.

The unding o several new endowed chairs throughout the

year bolstered research eorts, as well. An unexpected beuest o

more than $5.8 million rom a Laguna Beach, Cali., couple whose

amily member was treated at City o Hope in the 1960s established

the Edward and Estelle Alexander Chair in Inormation Sciences.

As the rst holder o the new chair, City o Hope Cancer Center

Associate Director Joyce C. Niland, Ph.D., will continue leading

City o Hopes collaborations with other cancer centers to create a

global inormation model to speed uture biomedical research.

Stephen J. Forman, M.D., was named as the rst holder o the

Francis and Kathleen McNamara Distinguished Chair in Hematology

and Hematopoietic Cell Transplantation, established by a $2.5 million

git rom Kathleen McNamara, a patient o Formans, and her

husband, Francis Chip McNamara.

Another $2.5 million git rom the amily o late City o Hope

patient and prominent Las Vegas builder Martin Collins established

the Pauline and Martin Collins Family Chair in Urology. The rst

holder is Timothy Wilson, M.D., director o the Department o

Urology & Urologic Oncology and the Prostate Cancer Program.

Furthering years o commitment to City o Hope, Sheri

Biller, vice chair o the board o directors at City o Hope, and her

husband, Les, were inspired to enhance the institutions patient

support services. Aiming to create a single place where patients and

amilies can turn or help in coping with cancer, the Sheri & Les

Biller Family Foundation pledged $2 million to establish the Sheri &

Les Biller Patient and Family Resource Center.

Continuing their steadast support, more than 30 industry

groups generated tens o millions o dollars through undraising

Mche am

7/31/2019 COH AR 2006

33/54


endeavors such as Spirit o Lie galas and gol tournaments. The

Home Furnishings Industry raised a record $10 million, including

the $6 million Amini git, during their annual undraising eort.

The National Oce Products Industrys Give. Hope. campaign

yielded more than $6.2 million, while the Hardware/Homebuilding

Industry raised more than $3 million. Members o the ood and drug

industries groups in the western United States and Arizona raised

more than $4.8 million. And, urthering more than three decades o

support, the Music and Entertainment Industry generated more than

$3 million through its annual campaign.Additional entertainment industry support came through

promotional spots recorded by nine-time Grammy-winner and breast

cancer survivor Sheryl Crow. The spots began running nationwide

in all 2006 through airtime donated by Premiere Radio Networks

and Movie Tunes, raising City o Hopes prole across the country.

The ads reached more than 190 million radio listeners and played in

16,500 movie theaters in the United States.

Through alliances with national brands including 3M,

Hansens, Kelloggs, Oce Depot, OceMax, Mattel, Sanord and

Unilever, cause-related marketing programs raised a total o nearly

$4 million or City o Hope. Staples, one o the organizations largest

cause-marketing participants in 2006, created customer-donated

programs that garnered nearly $1 million and generated invaluable

national visibility or City o Hope.

Epitomizing the commitment o City o Hopes thousands

o auxiliary members nationwide, decades-long supporter Morris

(Morrie) Darnov and his daughter, Sharon, generously donated a

combined git o$2 million in memory o Natalie Darnov, Morries

wie and Sharons mother. For more than our decades, Natalie and

Morrie Darnov served as dedicated members o Los Angeles Git o

Lie Chapter. Morrie remains an active chapter member.

More than 22,000 participants in nine cities around the

nation raised more than $2.5 million in an eort to eradicate the

most prevalent cancer in women through City o Hopes national

campaign, Walk or Hope to Cure Breast Cancer. Increased

team participation and support rom national sponsors such as

Wells Fargo, 3M Post-It Sticky Notes, Hilton HHonors, Good

Housekeepingmagazine, Orbitz and Sandals/Beaches resorts, as

well as cash sponsors Bamboo, Anne Michelle and Sebastian Body

Double, all contributed to a successul Walk season.

Eee d Edwd aexd

7/31/2019 COH AR 2006

34/54


7/31/2019 COH AR 2006

35/54


FiNANCiALS

Pe ifm

(For scal years beginning October 1 and ending September 30)

(dollar amounts in thousands)

Chge f Pe sevce 2006 % 2005 %

Medicare $ 231,246 25.4% $ 178,393 24.3%

Indemnity insurance 2,975 0.3% 8,266 1.1%

Managed care contracts 523,300 57.3% 422,939 57.4%

Subsidized care 155,332 17.0% 126,633 17.2%

Total $ 912,853 100.0% $ 736,231 100.0%

Pyme receved f Pe sevce 2006 % 2005 %

Medicare $ 56,503 17.1% $ 47,212 17.5%

Indemnity insurance 2,123 0.6% 3,296 1.2%

Managed care contracts 225,299 67.8% 199,242 73.7%

Medi-Cal and other 48,270 14.5% 20,463 7.6%

Total $ 332,195 100.0% $ 270,213 100.0%

Pe teed (ed dm) 2006 2005

New patient reerrals 6,419 6,148

Patients treated during year 17,695 16,894

Admissions 4,934 4,643

Patient days 49,330 43,745Clinic and inusion visits 109,603 102,605

Bone marrow transplants (BMT) 605* 460*

*includes BMT perormed at City o Hope Banner Good Samaritan

7/31/2019 COH AR 2006

36/54


Cy f Hpe d afe Cmed seme f Fc P



assEts

Cue ae 2006 2005*

Cash and cash euivalents $ 49,473 $ 51,041

Investments 71,072 53,437

Patient accounts receivable, less allowances or uncollectibleaccounts o $3,377 in 2006 and $2,010 in 2005 64,415 52,971

Grants and other receivables 15,187 9,288

Donor restricted unconditional promises to give, net 10,588 11,867

Prepaid and other 28,291 15,322

Total current assets $ 239,026 $ 193,926

PROPERTY, PLANT AND EqUIPMENT, net o accumulateddepreciation o $273,123 in 2006 and $242,257 in 2005 $ 371,440 $ 366,246

ohe ae

Investments $ 9,133 $ 5,334

Board-designated investments 161,234 136,002

Bond trust unds 41,774 12,367

Escrow unds 1,699

Donor restricted assets 128,989 94,236

Other assets 11,870 10,532

Total other assets 353,000 260,170

TOTAL ASSETS $ 963,466 $ 820,342

*Certain reclassications were made to the 2005 nancial statements to conorm to the 2006 presentation.

7/31/2019 COH AR 2006

37/54




liabilitiEs anD nEt assEts

Cue le 2006 2005*

Accounts payable and accrued liabilities $ 72,281 $ 98,545

Long-term debt, current portion and accrued interest 14,015 10,349

Total current liabilities 86,296 108,894

LONG-TERM DEBT, net o current portion and unamortizeddiscount o $2,131 and $2,259 as o September 30, 2006and 2005, respectively 241,144 191,613

ANNUITY AND SPLIT-INTEREST AGREEMENT OBLIGATIONS 19,670 19,037

Other 7,036 5,608

Total liabilities $ 354,146 $ 325,152

CoMMitMEnts anD ContinGEnCiEs

ne ae

Unrestricted $ 457,589 $ 382,940

Restricted 151,731 112,250

Total net assets 609,320 495,190

TOTAL LIABILITIES AND NET ASSETS $ 963,466 $ 820,342

*Certain reclassications were made to the 2005 nancial statements to conorm to the 2006 presentation.

7/31/2019 COH AR 2006

38/54


Cy f Hpe Cmed seme f acve



reveue 2006 2005

Net patient service revenues $ 332,195 $270,213

Contributions and net special event revenues 124,867 85,645

Royalties and research grants 151,884 123,754

Other 32,330 23,995

Total revenues $ 641,276 $503,607

Expee

Program services $ 441,862 $370,107

Supporting services 83,780 82,437

Total expenses 525,642 452,544

Operating income 115,634 51,063

Change in net unrealized (loss) gain on investments (998) 6,755

Loss on interest rate swap agreement (506)

FEMA grant used or eligible construction projects 272

Changes in net assets 114,130 58,090

Net assets, beginning o year 495,190 437,100

Net assets, end o year $ 609,320 $495,190

7/31/2019 COH AR 2006

39/54


Cy f Hpe Cmed seme f Ch Fw



Ch Fw fm opeg acve 2006 2005

Changes in net assets $114,130 $ 58,090

Adjustments to reconcile changes in net assets to net cashprovided by operating activities:

Depreciation and amortization 31,333 24,103

Unrealized (loss) gain on investments 998 (6,755)

Other changes in operating assets and liabilities (59,830) (17,321)

Total adjustments (27,499) 27

Net cash provided by operating activities $ 86,631 $ 58,117

Ch Fw fm iveg acve

Proceeds rom sales o property, plant and euipment $ 416 $ 786

Additions to property, plant and euipment (36,212) (56,707)

Change in investments (95,632) (21,560)

Net cash used in investing activities $(131,428) $ (77,481)

Ch Fw fm Fcg acve

Net cash provided by nancing activities $ 43,229 $ 33,066

Net increase in cash and cash euivalents (1,568) 13,702

Cash and cash euivalents, beginning o year 51,041 37,339

Cash and cash euivalents, end o year $ 49,473 $ 51,041

7/31/2019 COH AR 2006

40/54


and Tumor Immunology, and the departments o

Gene Regulation and Drug Discovery, Surgical

Research and Radiation Biology provide the

ramework or the institutes work.

national MEDiCal CEntEr

The National Medical Center is the place where

more than 138 physicians representing 25 board-

certied specialties help bring City o Hopes

research ull circle. Here, new and promisingtreatment options are made available to patients

long beore they become available in the community.

At any given time, City o Hope conducts more

than 300 clinical studies, involving 40 percent

o its eligible patients. The national average is less

than 5 percent.

Helord Clinical Research Hospital at

City o Hope, which opened in 2005, began a

new chapter in City o Hopes mission o bringing

cures to people battling cancer and other lie-

threatening illnesses. This state-o-the-art acility isthe culmination o decades o scientic, clinical

and undraising eorts. It embodies the organiza-

tions medical and technological expertise and

treatment approaches.

CEntEr For bioMEDiCinE & GEnEtiCs anD

tHE sYlVia r. & isaDor a. DEUtCH CEntEr For

aPPliED tECHnoloGY DEVEloPMEnt

Made possible by generous support rom the

National Oce Products Industry, the Center or

Biomedicine & Genetics (CBG) is licensedby the state and ederal government to produce

pharmaceutical-grade therapeutic compounds. This

provides a cost-eective way to expedite the delivery

o experimental biological therapies to patients.

City o Hope established the CBG to ensure that its

technological innovations are eciently translated

rom the research lab to the clinical setting, while

allowing scientic and clinical investigators the

PROgRAMSAND FACiLiTiES

CoMPrEHEnsiVE CanCEr CEntEr

A National Cancer Institute (NCI) Cancer Center

since 1981, City o Hope received the prestigious

comprehensive designation rom the NCI in 1998,

and it was renewed in 2004. This designation makes

City o Hope one o only a ew such centers in the

United States that combines all acets o cancer

research and care with the highest standards o

excellence. An additional component o the NCI

designation includes community outreach, educationand population-based research. City o Hopes

recently created Division o Population Sciences

addresses this by ocusing on understanding the

origins o cancer, as well as research to better

comprehend long-term outcomes o treatment.

City o Hope also sponsors community outreach

and education orums targeting both health-care

proessionals and the public. Through all o these

activities combined, NCI-designated cancer centers,

like City o Hope, play an important role in their

communities, infuencing standards o cancerprevention and treatment.

bECKMan rEsEarCH institUtE

With a sta o more than 545, including nearly

80 principal scientists, City o Hopes Beckman

Research Institute is one o the nations premier

centers or groundbreaking biomedical research.

City o Hope scientists undertake undamental

investigations in molecular genetics and cellular

biology; they study normal and abnormal biological

processes, including mutagenesis and DNA repair,cell dierentiation and early development, inter-

and intracellular signaling, RNA processing and

genome structure. These scientists have achieved

major advances in recombinant DNA technology,

monoclonal antibodies, gene therapy and radioim-

munotherapy. The divisions o Biology, Immunology,

Neurosciences, Molecular Medicine, Molecular

Biology, Virology and Cancer Immunotherapeutics

7/31/2019 COH AR 2006

41/54


reedom to test and rene the most promising new

therapeutics. As a National Gene Vector Laboratory,

the CBG is also responsible or the production o

plasmid DNA vectors or ederally unded gene

therapy research. In recognition o their generous

git, the rst foor o the CBG acility is named the

Sylvia R. & Isador A. Deutch Center or Applied

Technology Development.

GEnEral CliniCal rEsEarCH CEntErThe General Clinical Research Center (GCRC) at

City o Hope, a partnership with the University

o Southern Caliornia, is one o only 59 centers

nationwide unded by the National Center or

Research Resources o the National Institutes o

Health. The GCRC provides an optimal

setting or medical investigators to conduct sae,

controlled, state-o-the-art inpatient and

outpatient studies. GCRC resources include highly

trained research personnel, a core laboratory, a

bioinormatics system and a metabolic kitchen.The GCRC research sta includes nurses,

dietitians, biostatisticians, skilled technicians and

administrative personnel to help investigators by

acilitating the day-to-day research process and

assisting the research patients in a supportive

and ecient environment.

GraDUatE sCHool oF bioloGiCal sCiEnCEs

For 13 years, City o Hopes accredited Graduate

School o Biological Sciences has provided a

uniue training ground or tomorrows scientists. Itoers postgraduate training in molecular biology,

immunology, molecular medicine and neurosciences,

including academic classes and intensive laboratory

research. Working toward the completion o their

doctoral degrees, students have access to state-o-

the-art acilities and shared resources to acilitate

their research and are able to collaborate alongside

aculty who are experts in their elds.

CitY oF HoPE bannEr GooD saMaritan

bonE MarroW transPlantation (bMt)

ProGraM

In partnership with Banner Health System,

City o Hope has built a successul satellite BMT

program in Phoenix, serving area residents. This

joint program has been designated as a member o

the Southwest Oncology Group, one o the largest

o the National Cancer Institute-supported cancer

clinical trials cooperative groups in the UnitedStates. This provides patients with access to key

clinical trials and research protocols.

soUtHErn CaliFornia islEt CEll

rEsoUrCE CEntEr

Housed in the Leslie and Susan Gonda (Goldschmied)

Diabetes and Genetic Research Center, the Southern

Caliornia Islet Cell Resource (SC-ICR) center

is one o only seven islet cell resource (ICR) centers

unded by the National Institutes o Health.

City o Hope perormed the most islet transplantsin the U.S. in 2004 and 2005 and distributed the

largest number o islets to basic science programs

throughout the U.S. since 2004. During the most

recent unding period o the ICR program,

City o Hope was the only center unded in the

western U.S. In May 2004, City o Hope became the

rst islet transplant center without a whole organ

transplantation program to become a member o the

United Network o Organ Sharing. Additionally, in

2006, City o Hope was designated an islet cell

transplant center by the Juvenile Diabetes ResearchFoundation, making it one o only 14 institutions

in the U.S. to receive this distinction and the only

one in Southern Caliornia. The center also oers a

total-care diabetes and endocrinology program and

has helped millions o diabetics worldwide who

benet rom synthetic human insulin developed

through research conducted at City o Hope.

7/31/2019 COH AR 2006

42/54


RESEARCH AND CLiNiCALDiviSiONS, DEPARTMENTSAND PROgRAMS


rEsEarCH ProGraMs anD FaCilitiEs

Cancer Biology

Cancer Control and Population Sciences

Cancer Immunotherapeutics

Developmental Cancer Therapeutics

Hematologic Malignancies


DiVisions

Biology

Cancer Immunotherapeutics and

Tumor Immunology

Immunology

Molecular Biology

Molecular Medicine

Neurosciences

Virology

national MEDiCal CEntEr DiVisions/

DEPartMEnts

Anesthesiology

Diagnostic Radiology

Nuclear Medicine

Hematology & Hematopoietic Cell TransplantationHematopoietic Stem Cell and

Leukemia Research

Inormation Sciences

Biomedical Inormatics

Biostatistics

Clinical Research Inormation Management

Medical Oncology & Therapeutics Research

Aging and Cancer Research Program

Clinical and Molecular Pharmacology

Medical Specialties

CardiologyDiabetes, Endocrinology & Metabolism

Gastroenterology

Inectious Diseases

Neurology

Psychology

Pulmonary and Critical Care Medicine

Supportive Care & Palliative Medicine

Pathology

Anatomic Pathology

Clinical Pathology

Transusion MedicinePediatrics

Population Sciences

Behavioral Oncology

Center or Cancer Survivorship

Center o Community Alliance or Research

& Education

Clinical Cancer Genetics

7/31/2019 COH AR 2006

43/54


Etiology

Nursing Research and Education

Outcomes Research/Intervention

Radiation Oncology

Clinical Radiation Oncology

Radiation Biology

Radiation Physics

Surgery

General and Oncologic Surgery

Neurosurgery

Orthopaedic Surgery

Plastic and Reconstructive Surgery

Surgical Research

Thoracic Surgery

Urology and Urologic Oncology

national MEDiCal CEntEr DisEasE-

sitE ProGraMs

Brain Tumor Program

Breast Cancer Program

Rita Cooper Finkel and J. William Finkel

Womens Health Center

Diabetes, Endocrinology & Metabolism

Gene Regulation and Drug Discovery

Islet Cell Transplantation Program

Gastrointestinal Cancer Program

General Clinical Research Center

Genitourinary/Prostate Cancer Program

Gynecologic Cancer ProgramLiver Cancer Program

Lymphoma SPORE

Musculoskeletal Tumor Program

Pediatric Cancer Program

Thoracic/Lung Cancer Program

7/31/2019 COH AR 2006

44/54


ADMiNiSTRATivE LEADERSHiPAND BOARD OF DiRECTORS

aDMinistration

Michael A. Friedman, M.D.

President and

Chie Executive Ofcer

Terry W. Blackwood, C.P.A.

Chie Financial Ofcer and

Treasurer

Debra F. Fields, J.D.

Chie Risk Ofcer

Kathleen L. Kane, J.D.

Executive Vice President,

Development and

External Aairs

Theodore G. Krontiris, M.D., Ph.D.

Executive Vice President,

Medical and Scientifc Aairs

Director, NCI-designated

Comprehensive Cancer Center

Alexandra M. Levine, M.D.

Chie Medical Ofcer

Virginia A. Opipare

Executive Vice President and

Chie Operating Ofcer

Arthur D. Riggs, Ph.D.

Director, Beckman Research

Institute

Chris A. Roederer

Chie Corporate Services Ofcer

Robert W. Stone, J.D.

General Counsel and Secretary

boarD oF DirECtors

Chair

Philip L. Engel

Immediate Past Chair

Jack R. Suzar*

Vice Chairs

Sheri J. Biller

Terry R. Peets, Chair-elect

Chairs Emeritus

Meyer E. Hersch*

Gil N. Schwartzberg,* J.D.

Richard S. Ziman*

General Vice Chair

Ben Horowitz

Members

Donald Bailey Sr.

Robert A. Cook

L. Dale Crandall

Israel J. Freeman

Robbin L. Itkin

Stephen B. Kass

Jerey G. Katz

Jacueline B. Koseco, Ph.D.

Thomas A. Madden

Robert G. Miller

Gail K. Naughton, Ph.D.

John R. Ohanesian

Norman C. Payson, M.D.

Claire L. RothmanJoseph P. Sanord

Laura A. Schulte

Ernie C. So

Stephan E. Tow

Honorary Directors

Michael B. Kaplan,* J.D.

Sidney L. Kline*

Mark B. Levey*

MEDiCal CEntEr boarD

oF DirECtors

Chair


Vice Chair

Ernie C. So

Members

Donald S. David, M.D.

Mordecai N. Dunst, M.D.Israel J. Freeman

Donald W. Homan

Ben Horowitz

Robbin L. Itkin

Robert J. Morgan, M.D.

Richard B. Myers*

Claire L. Rothman

Iris Rothstein*

Andrew Spiegl*

Esther A. Torrez*

bECKMan rEsEarCH

institUtE boarD oF

DirECtors

Chair

Stephen B. Kass

Members

Gary E. Freedman

Ben Horowitz


Harry Levitt

Elliot Rosman

John J. Rossi, Ph.D.

Iris Rothstein*

Ernie C. So

*Also on the Board o Regents

7/31/2019 COH AR 2006

45/54


CHairs oF tHE boarD

Barnett Cohen (1913-1920)

Benjamin Forer (1920-1922)

Dr. Henry Silverberg (1922-1925)

J.A. Rosenkranz (1925-1926,

1933-1936, 1939-1941)

Dr. Nahum Kavinoky (1926-1927)

Chaim Shapiro (1927-1929)

Dr. Moses I. Devorkin

(1929-1931)

Lester W. Roth (1931-1933)

Mark Carter (1936-1939)

Pinches Karl (1941-1944)

Ben Solnit (1944-1946)

Louis Tabak (1946-1949,

1957-1961)

Victor M. Carter (1949-1957)

Seymour Gra(1961-1964)

Emanuel H. Fineman (1964-1971)

Percy Solotoy (1971-1975)

Meyer E. Hersch (1975-1983)

Abraham S. Bolsky (1983-1989)

Richard S. Ziman (1989-1995)

Gil N. Schwartzberg, J.D.

(1995-1999)

Jack R. Suzar (1999-2004)

Philip L. Engel (2004-present)

boarD oF rEGEnts

Chair

Jack R. Suzar

Chairs Emeritus

Meyer E. Hersch

Gil N. Schwartzberg, J.D.

Richard S. Ziman

Members

Rhoda K. EhrlichBonnie L. Fein

John T. Frankenheimer, J.D.

Leon Frieden

Richard D. Gibbs

Robert N. Goodman

Michael Greenberg

Zachary I. Horowitz

Louise Horvitz, M.S.W., Psy.D.

Bryan Isaacs

Michael B. Kaplan, J.D.

Sidney L. Kline

Laurie Konheim

Mark B. Levey

Rhoda Makadon

David Z. Marmel

Jack L. Meyers

David Morse

Richard B. Myers

Mark Oli

Ricky Paskow

Iris Rothstein

Nina Madden Sabban

Clarence T. Schmitz

Judge Bernard Selber

Bernard J. Siegel

Andrew Spiegl

Adrienne Ehrlich Stern

Bobbie M. Stern

Esther A. Torrez

Dan E. Young

7/31/2019 COH AR 2006

46/54


FACuLTy LEADERSHiP


THEODORE G. KRONTIRIS, M.D., Ph.D.

Director

Executive Vice President, Medical and Scientifc

Aairs

RICHARD JOVE, Ph.D.

Deputy Director

MICHAEL BENEDICT, Pharm.D.

Associate Director or Administration

SMITA BHATIA, M.D., M.P.H.

Associate Director or Population Research

ROBERT A. FIGLIN, M.D.Associate Director or Clinical Research

JOYCE C. NILAND, Ph.D.

Associate Director or Inormation Sciences

JOHN J. ROSSI, Ph.D.

Associate Director or Laboratory Research

YUN YEN, M.D., Ph.D.

Associate Director or Translational Research

Cce bgy Pgm


Co-leader

GERD P. PFEIFER, Ph.D.

Co-leader

Cce C d Ppu scece

Pgm


Co-leaderMARCIA GRANT, R.N, D.N.Sc.

Co-leader

Cce immuhepeuc Pgm

ANDREW A. RAUBITSCHEK, M.D.

Co-leader

MICHAEL C. JENSEN, M.D.

Co-leader

Devepme Cce thepeuc Pgm

RICHARD JOVE, Ph.D.

Co-leader


Co-leader

Hemgc Mgce Pgm

STEPHEN J. FORMAN, M.D.

Co-leader

RAVI BHATIA, M.D.

Co-leader


ARTHUR D. RIGGS, Ph.D.

Director

SUSAN E. KANE, Ph.D.

Associate Director

Dv f bgy

GERD P. PFEIFER, Ph.D.

Chair

7/31/2019 COH AR 2006

47/54


Dv f Cce immuhepeuc d

tum immugy


Chair

Director, Department o Radioimmunotherapy

MICHAEL C. JENSEN, M.D.

Associate Chair


Clinical DirectorDv f immugy

JOHN E. SHIVELY, Ph.D.

Chair

Dv f Mecu bgy


Chair

Lidow Family Research Chair

Dv f Mecu Medce

RICHARD JOVE, Ph.D.

Chair

STEVE S. SOMMER, Ph.D.

Director, Department o Molecular Genetics

Director, Department o Molecular Diagnosis

Dv f neucece

MICHAEL E. BARISH, Ph.D.

Chair

Dv f Vgy

JOHN A. ZAIA, M.D.

Chair

national MEDiCal CEntEr DiVisions/

DEPartMEnts/ProGraMs

Dv f aehegy

MICHAEL LEW, M.D.

Chair

Dv f Dgc rdgy

J. MARTIN HOGAN, M.D.

Chair

Depme f nuce Medce

DAVE YAMAUCHI, M.D.

Director

Dv f Hemgy & Hempec Ce

tp

STEPHEN J. FORMAN, M.D.Chair

Francis and Kathleen McNamara Distinguished

Chair in Hematology and Hematopoietic

Cell Transplantation

AUAYPORN NADEMANEE, M.D.

Associate Clinical Director

MARGARET ODONNELL, M.D.

Associate Clinical Director

DAVID S. SNYDER, M.D.

Associate Director

acue Myegeu leukem Pgm

ANTHONY STEIN, M.D.

Director

Cc reech Pgm

EILEEN SMITH, M.D.

Associate Director

Hempec Ce thepe ly

DAVID DIGIUSTO, Ph.D.

Director

Depme f Hempec sem Ce d

leukem reech

RAVI BHATIA, M.D.

Director

Hcmpy ly

DAVID SENITZER, Ph.D.

Director

7/31/2019 COH AR 2006

48/54


immugy Ceve sude ly

MICHAEL KALOS, Ph.D.

Director

lg-em Fw-up Pgm


Director

Medc Educ & tg Pgm

AMRITA KRISHNAN, M.D.

DirectorMched Ueed D Hempec Ce

tp Pgm

AUAYPORN NADEMANEE, M.D.

Director

Director, Lymphoma Program

new Dug Devepme

MARK KIRSCHBAUM, M.D.

Director

Dv f ifm scece/bc

JOYCE C. NILAND, Ph.D.Chair

Edward and Estelle Alexander Chair in

Inormation Sciences

Depme f bmedc ifmc

DOUGLAS C. STAHL, Ph.D.

Director

Depme f bc

JEFFREY LONGMATE, Ph.D.

Director

Depme f Cc reech ifm

Mgeme

DINA JOHNSON

Director

Dv f Medc ocgy & thepeuc

reech

ROBERT A. FIGLIN, M.D.

Chair

Arthur and Rosalie Kaplan Proessor o Medical

Oncology

agg d Cce reech Pgm

ARTI HURRIA, M.D.

Director

Depme f Cc d Mecu

Phmcgy


Director

Dv f Medc spec

K. VENKATARAMAN, M.D.

Chair

Depme f Cdgy

K. VENKATARAMAN, M.D.

Director

Depme f Dee, Edcgy &

Mem

FOUAD R. KANDEEL, M.D., Ph.D.

Director

Depme f Geegy

DONALD DAVID, M.D.

Director

President, Medical Sta

Depme f ifecu Dee

JAMES I. ITO, M.D.Director

Depme f neugy

HARRY O. OPENSHAW, M.D.

Director

Depme f Pychgy

MARTIN PEREZ, Ph.D.

Co-director

7/31/2019 COH AR 2006

49/54


ANDREA THORNTON, Ph.D.

Co-director

Depme f Pumy d Cc Ce

Medce

DAVID A. HORAK, M.D.

Director

Depme f suppve Ce &

Pve Medce

NEAL SLATKIN, M.D.Director

Dv f Phgy

LAWRENCE M. WEISS, M.D.

Chair

Depme f amc Phgy/Cygy

SHARON P. WILCZYNSKI, M.D., Ph.D.

Director

Depme f Cc Phgy

KAREN L. CHANG, M.D.

Director

Depme f Cygeec

MARILYN SLOVAK, Ph.D.

Director

Depme f tfu Medce

JOY FRIDEY, M.D.

Director

Dv f Pedc

JUDITH K. SATO, M.D.

Acting Chair

Director, Department o Pediatric Hematology/

Oncology

JOSEPH ROSENTHAL, M.D.

Director, Department o Pediatric Hematopoietic

Cell Transplantation

Dv f Ppu scece


Chair

Cee f Cce suvvhp


Medical Director

WENDY LANDIER, R.N., M.S.N.

Clinical Director

Cee f Cmmuy ace f reech &Educ

KIMLIN TAM ASHING-GIWA, Ph.D.

Director

Depme f Cc Cce Geec

JEFFREY N. WEITZEL, M.D.

Director

Depme f nug reech d Educ

MARCIA GRANT, R.N, D.N.Sc.

Director

Depme f oucme reech/

ieve


Director

Dv f rd ocgy

JEFFREY Y.C. WONG, M.D.

Chair

Cc rd ocgy


Director

Depme f rd bgy

BINGHUI SHEN, Ph.D.

Director

Depme f rd Phyc

TIMOTHY E. SCHULTHEISS, Ph.D.

Director

Proessor, Division o Radiation Oncology

7/31/2019 COH AR 2006

50/54


Dv f sugey

I. BENJAMIN PAZ, M.D.

Co-chair

TIMOTHY G. WILSON, M.D.

Co-chair

Depme f Gee ocgc sugey


Director

Depme f neuugeyBENHAM BADIE, M.D., F.A.C.S.

Director

Depme f ohpedc sugey

J. DOMINIC FEMINO, M.D.

Director

Depme f Pc d recucve

sugey

JAMES S. ANDERSEN, M.D.

Director

Depme f sugc reech

SHIUAN CHEN, M.D.

Director

Depme f thcc sugey

KEMP H. KERNSTINE, M.D., Ph.D.

Director

Depme f Ugy d Ugc ocgy


Director

Pauline and Martin Collins Family Chair

in Urology

DisEasE-sitE ProGraMs

b tum Pgm

BENHAM BADIE, M.D.

Director

be Cce Pgm


Co-director, Breast Cancer Program

Director, Rita Cooper Finkel and J. William Finkel

Womens Health CenterGEORGE SOMLO, M.D.

Co-director, Breast Cancer Program

Director, Breast Oncology

Associate Director, High-dose Chemotherapy,

Division o Medical Oncology & Therapeutics

Research

Director, Multiple Myeloma Program

Depme f Dee, Edcgy & Mem


DirectorDepme f Gee regu d

Dug Dcvey

BARRY M. FORMAN, M.D., Ph.D.

Ruth B. and Robert K. Lanman Endowed

Chair in Gene Regulation and Drug

Discovery Research

ie Ce tp Pgm


Director

Ge Cce PgmSTEPHEN SHIBATA, M.D.

Director

JOSHUA ELLENHORN, M.D.

Associate Director

7/31/2019 COH AR 2006

51/54


Gee Cc reech Cee

JOHN A. ZAIA, M.D.

Director

Geuy/Pe Cce Pgm


Director


Associate Director

Gyecgc Cce PgmMARK WAKABAYASHI, M.D., M.P.H.

Director

lve Cce Pgm

LAWRENCE D. WAGMAN, M.D.

Director

lymphm sPorE


Principal Investigator


Co-principal Investigator

Pedc/Mucukee Cce Pgm

JUDITH A. SATO, M.D.

Co-director

J. DOMINIC FEMINO, M.D.

Co-director

thcc/lug Cce Pgm

KEMP H. KERNSTINE, M.D., Ph.D.

Director

otHEr institUtional rEsoUrCEs

am reuce Cee

RICHARD ERMEL, D.V.M., Ph.D.

Director

Cee f apped techgy Devepme

LARRY A. COUTURE, Ph.D.

Senior Vice President

Cee f bmedce & Geec

DAVID HSU, Ph.D.

Director

techgy lceg

BRIAN R. CLARK, Ph.D.

DirectorCee f Gdue & Pfe sude

SUSAN E. KANE, Ph.D.

Senior Vice President, Academics

STEVEN NOVAK, Ph.D.

Director, Academics

Gdue sch f bgc scece


Dean

Depme f Cug Medc Educ

ROBERT J. MORGAN JR., M.D.

Director

7/31/2019 COH AR 2006

52/54


LOCATiONS

Cy f Hpe d

beckm reech iue

1500 East Duarte Road

Duarte, Cali. 91010-3000

800-423-7119

www.cityohope.org

Cy f Hpe

Devepme Hedque

1055 Wilshire BoulevardLos Angeles, Cali. 90017

800-544-3541

Cy f Hpe

be Gd sm

be Mw tp

Pgm

1111 East McDowell Road,

Suite 12b

Phoenix, Ariz. 85006

reg Devepme ofce

SOuTHEAST

Fort Lauderdale, Fla.

800-584-6709

MiDWEST

Chicago

800-779-5893

NORTHEAST

Philadelphia

800-344-8169

SOuTHWEST

San Diego

888-805-8911

Phoenix

800-732-7309

Palm Desert, Cali.

800-732-7121

Orange County, Cali.

800-235-0579

NORTHWEST

San Francisco

800-732-7140

Seattle

800-934-9196

Prodced b: Ct of Hope Commncatons Department nder the drecton of Senor vce Presdent Brenda Maceo

Project Manaer: Tana M. Marn

Wrters: gre voel, Stee Krk, Tana Marn, Alca D Rado

Art Drecton and Desn:The Jefferes Assocaton

Prncpal Photoraph: Phl Channn

Prnted b: Colorgraphcs Los Aneles

7/31/2019 COH AR 2006

53/54

7/31/2019 COH AR 2006

54/54

1500 East Duarte Road

Duarte, Calif. 91010-3000

Documents

COH AR 2006